Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
SELEXIS
Download detailed PDF Members: July 2005Opening of the new R&D facility in Plan-les-OuatesSelexis is a private, Swiss-based biotechnology company leading the development of innovative solutions using proprietary technologies and expression systems for the rapid production of proteins for R&D and therapeutic applications. Industry experts are looking for novel and innovative solutions to increase the yields of recombinant proteins and to rapidly advance products into production for clinical phases.Referred to as MARtech, Matrix Attachment Region technologies provide powerful and flexible integrated solutions for cellular protein production. Selexis’ MARtech offers a number of significant advantages over traditional approaches including:- Acceleration of drug discovery by reducing the development time up to 8 months. Knowing that a delay of a single day can cost a pharmaceutical company between US$1 million and US$13 million in lost sales, this is a huge benefit.
This page has been viewed 414 times since April 2007, the link to the organisation's website has been followed 55 times Recent Search Terms used to find this page: Selexis home | selexis 2007 | f | matrix attachment region selexis | martech technology selexis | selexis drug | selexis | . Search for more companies in San Francisco Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for SELEXIS | |||||||||||||||||||||||||||||||||||||||||
|